Frank H Laukien bought $1.0M of Bruker (BRKR)
Executed Feb 18 2025, disclosed Feb 19 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Feb 19 2025), the stock returned -6.9% (delay-adjusted); from the execution session (Feb 18 2025), -7.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
Frank H Laukien (PRESIDENT & CEO) filed 3 Form 4 reports in the past 24 months (3 purchases, 0 sales), most often in Bruker Corporation (BRKR). Across 3 priced purchase filings, the average 21-session return was +5.6% from execution and +5.1% from disclosure (delay-adjusted; derived). The largest single filing was $5.0M of BRKR (100,000 sh across 3 lots, as filed), executed Nov 18 2024.
Healthcare · Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diag…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→2,608 sh × $38.36
Exec Jun 6 2025
Filed Jun 9 2025 · 5:30 PM ET BRKRPURCHASE Bruker Corporation $5.0M
100,000 sh across 3 lots
Exec Nov 18 2024
Filed Nov 19 2024 · 5:30 PM ET